Squarepoint Ops LLC Grows Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Squarepoint Ops LLC grew its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 56.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 79,537 shares of the company's stock after purchasing an additional 28,662 shares during the quarter. Squarepoint Ops LLC owned approximately 0.25% of Delcath Systems worth $958,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Jefferies Financial Group Inc. acquired a new stake in Delcath Systems during the 4th quarter worth $251,000. Principal Financial Group Inc. increased its stake in Delcath Systems by 28.8% in the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock valued at $1,387,000 after purchasing an additional 25,736 shares during the period. Private Advisor Group LLC purchased a new stake in shares of Delcath Systems in the fourth quarter valued at about $153,000. Jane Street Group LLC boosted its stake in shares of Delcath Systems by 1,364.6% during the fourth quarter. Jane Street Group LLC now owns 178,797 shares of the company's stock worth $2,153,000 after buying an additional 166,589 shares during the period. Finally, Simplify Asset Management Inc. purchased a new position in shares of Delcath Systems during the fourth quarter worth about $205,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on DCTH. Wall Street Zen cut Delcath Systems from a "strong-buy" rating to a "buy" rating in a research report on Sunday. HC Wainwright reiterated a "buy" rating and issued a $29.00 target price (up from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $24.00.

Delcath Systems Price Performance

Shares of DCTH stock traded down $0.22 during mid-day trading on Tuesday, hitting $16.08. The stock had a trading volume of 361,104 shares, compared to its average volume of 378,641. The firm has a market cap of $560.00 million, a PE ratio of -11.91 and a beta of 0.72. The company's 50-day simple moving average is $13.36 and its 200-day simple moving average is $13.27. Delcath Systems, Inc. has a fifty-two week low of $6.33 and a fifty-two week high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The firm had revenue of $19.80 million for the quarter, compared to analysts' expectations of $16.83 million. On average, analysts expect that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.